Ariflo for COPD
Executive Summary
GlaxoSmithKline's Ariflo (cilomilast) will be reviewed for treatment of chronic obstructive pulmonary disease by FDA's Pulmonary-Allergy Drugs Advisory Committee on Sept. 5. Glaxo submitted the NDA for Ariflo in December. The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m. [Editor's note: To 1sign up for a webcast or video of this meeting, go to FDAAdvisoryCommittee.com]...